Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04254133
Other study ID # RG1004177
Secondary ID P50CA097186NCI-2
Status Enrolling by invitation
Phase
First received
Last updated
Start date November 30, 2018
Est. completion date August 31, 2028

Study information

Verified date February 2024
Source Fred Hutchinson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This trial studies the role of inherited (present at birth) mutations in cancer risk genes such as BRCA2, BRCA1, ATM, CHEK2, and others in relation to prostate cancer. This study may help researchers understand the frequency and importance of inherited mutations in cancer risk genes in patients with prostate cancer and potentially help identify better ways to treat cancer in patients who have a mutation in one of these genes.


Description:

OUTLINE: Participants complete questionnaire over 20 minutes at baseline, then undergo collection of saliva sample for genetic testing. Participants identified to have an inherited mutation in a deoxyribonucleic acid (DNA) repair gene undergo genetic counseling. Participants whose genetic testing does not indicate an inherited mutation in a DNA repair gene receive a letter thanking them for their participation and emphasizing the importance of ongoing communication with their physician and family members about cancer risk. Participants will be sent newsletters every year to encourage study engagement and update health questionnaires every two years.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 1360
Est. completion date August 31, 2028
Est. primary completion date August 31, 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 35 Years to 89 Years
Eligibility Inclusion Criteria: Case Ascertainment - Signed informed consent form providing agreement for germline genetic testing, use and release of health and research information - Male aged 35 to 89 years - Diagnosis of prostate cancer - Resident of Washington state - Willing to complete a questionnaire (online or on paper) to provide basic demographic information, family cancer history, and health history - Willing and able to provide a saliva sample - United States (U.S.) mailing address Inclusion Criteria: Family Recruitment - Signed informed consent form providing agreement for germline genetic testing, use and release of health and research information - Males aged 35 to 89 years - Willingness to complete a questionnaire (online or on paper) to provide basic demographic information, family cancer history, and health history - Willingness and ability to provide a saliva sample - U.S. mailing address Exclusion Criteria: Case Ascertainment - Unable to provide informed consent, e.g. decisional impairment - Prior bone marrow transplant - Currently under treatment for a hematologic malignancy - Study team members Exclusion Criteria: Family Recruitment - Unable to provide informed consent, e.g. decisional impairment - Prior bone marrow transplant - Currently under treatment for a hematologic malignancy - Study team members

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Questionnaire
Complete questionnaire
Procedure:
Biospecimen Collection
Provide saliva samples
Diagnostic Test:
Genetic Testing
Undergo genetic testing
Other:
Genetic Counseling
Undergo counseling
Laboratory Biomarker Analysis
Correlative Studies

Locations

Country Name City State
United States Fred Hutch/University of Washington Cancer Consortium Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Fred Hutchinson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identification of a population-based cohort of men with prostate cancer (PC) and germline deoxyribonucleic acid (DNA) repair gene (gDRG) mutations Identification to be determined through the Washington State Cancer Registry and by genetic testing on saliva samples for inherited mutations in cancer risk genes such as BRCA2, BRCA1, ATM, and others in prostate cancer. From the start of study through death (up to 20 years)
Primary Clinical, pathologic, and molecular predictors of gDRG mutation carriers for men with PC Predictors to be identified by analyzing information provided by participants on their health history and potentially further testing or chart review on participants who consent to future contact. From the start of study through death (up to 20 years)
Primary Utility and feasibility of cascade genetic testing through use of family history of men with PC identified to have gDRG mutations To be determined by collection of information about participants' family history and subsequent analysis of cascade genetic testing outcomes. From the start of study through death (up to 20 years)
Primary Identification of a cohort of men with gDRG mutations without PC Identification to be determined through family history of men with PC identified through the Washington State Cancer Registry and by genetic testing on saliva samples for inherited mutations in cancer risk genes such as BRCA2, BRCA1, ATM, and others in prostate cancer. From the start of study through death (up to 20 years)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04457232 - Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation Phase 1
Active, not recruiting NCT03661437 - Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy Early Phase 1
Completed NCT02337465 - KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer N/A
Completed NCT03013413 - Ultrasound-Based Imaging Using the Aixplorer System in Diagnosing Prostate Cancer in Patients Undergoing Biopsy N/A
Recruiting NCT06037863 - Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial N/A
Active, not recruiting NCT03580499 - Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy N/A
Completed NCT03326440 - Virtual Environment Radiotherapy to Improve Patients' Compliance to Radiotherapy (RT) in Prostate Cancer N/A
Recruiting NCT04597359 - To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring Phase 2
Active, not recruiting NCT03263650 - Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC Phase 2
Active, not recruiting NCT04600336 - Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer Phase 2
Active, not recruiting NCT04299620 - Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy N/A
Completed NCT04976257 - Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion Early Phase 1
Completed NCT02957981 - The Genetic Education for Men Trial: Web-Based Education vs. Standard Care N/A
Withdrawn NCT03408561 - Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer N/A
Enrolling by invitation NCT06347809 - DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine
Recruiting NCT05519878 - Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers N/A
Recruiting NCT02994758 - Development of Diagnostics and Treatment of Urological Cancers N/A
Completed NCT01497431 - Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants Phase 1
Active, not recruiting NCT00002540 - Screening for Prostate Cancer in Older Patients (PLCO Screening Trial) N/A
Completed NCT03101046 - Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic Phase 2